Bromocriptine SRO in Parkinson's disease: Preliminary results

F. Stocchi, M. F. De Pandis, G. Fabbrini, S. Ruggieri, P. Bocciarelli, A. Agnoli

Research output: Contribution to journalArticlepeer-review


Bromocriptine SRO is a new galenic preparation which allows a slow release of the drug and the maintaining of more stable plasma levels of drug. Two groups of patients with a diagnosis of Parkinson's disease, 7 'de novo' and 8 with fluctuations in motor performance were studied. Patients were followed up to three months by means of clinical ratings every month. Results of the study show an improvement of disability in the 'de novo' and an increase in the number of hours spent in the 'on' passage with respect to 'off' phase in the fluctuating patients. No significant side effects were recorded.

Original languageEnglish
Pages (from-to)35-40
Number of pages6
JournalNew Trends in Clinical Neuropharmacology
Issue number2
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology


Dive into the research topics of 'Bromocriptine SRO in Parkinson's disease: Preliminary results'. Together they form a unique fingerprint.

Cite this